[go: up one dir, main page]

PL376231A1 - Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate - Google Patents

Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate

Info

Publication number
PL376231A1
PL376231A1 PL03376231A PL37623103A PL376231A1 PL 376231 A1 PL376231 A1 PL 376231A1 PL 03376231 A PL03376231 A PL 03376231A PL 37623103 A PL37623103 A PL 37623103A PL 376231 A1 PL376231 A1 PL 376231A1
Authority
PL
Poland
Prior art keywords
inhalation
salmeterol xinafoate
powdered medicament
tiotropium salt
tiotropium
Prior art date
Application number
PL03376231A
Other languages
Polish (pl)
Inventor
Hagen Graebner
Mareke Hartig
Peter Sieger
Rainer Soyka
Michael Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL376231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of PL376231A1 publication Critical patent/PL376231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03376231A 2002-12-20 2003-12-04 Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate PL376231A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20

Publications (1)

Publication Number Publication Date
PL376231A1 true PL376231A1 (en) 2005-12-27

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376231A PL376231A1 (en) 2002-12-20 2003-12-04 Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate

Country Status (21)

Country Link
EP (1) EP1581198A1 (en)
JP (1) JP2006516135A (en)
KR (1) KR20050086930A (en)
CN (1) CN1728988B (en)
AU (1) AU2003288226B2 (en)
BR (1) BR0317443A (en)
CA (1) CA2510779A1 (en)
DE (1) DE10351663A1 (en)
EA (1) EA010588B1 (en)
EC (1) ECSP055855A (en)
FR (1) FR2848849B1 (en)
HR (1) HRP20050570A2 (en)
IT (1) ITMI20032473A1 (en)
MX (1) MXPA05006519A (en)
NO (1) NO20053548L (en)
NZ (1) NZ541303A (en)
PL (1) PL376231A1 (en)
RS (1) RS20050484A (en)
UA (1) UA83813C2 (en)
WO (1) WO2004058233A1 (en)
ZA (1) ZA200503692B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JP4342426B2 (en) * 2004-11-24 2009-10-14 科研製薬株式会社 Itraconazole formulation for oral administration
WO2007017437A1 (en) * 2005-08-06 2007-02-15 Boehringer Ingelheim International Gmbh Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
PT1869035E (en) * 2005-12-19 2013-01-10 Sicor Inc Novel crystalline form of tiotropium bromide and process for preparation thereof
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
DE102007036411A1 (en) * 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg powder inhaler
PE20090907A1 (en) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (en) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Salt forms of organic compound.
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
KR101927068B1 (en) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
KR101748796B1 (en) * 2015-09-30 2017-06-19 한미약품 주식회사 Inhalation capsule with enhanced delivery rate of active ingredients
JP2019517542A (en) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin
TW202031293A (en) * 2018-11-13 2020-09-01 美商共結晶製藥公司 Formulations of influenza therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016031A1 (en) * 1992-02-11 1993-08-19 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (en) * 1992-02-11 2000-10-04 格拉克索公司 Drug material suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts
DE10104367A1 (en) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions containing betamimetics with fewer side effects
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
CA2459493C (en) * 2001-09-14 2011-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions for inhalation

Also Published As

Publication number Publication date
CA2510779A1 (en) 2004-07-15
NZ541303A (en) 2008-11-28
ZA200503692B (en) 2006-10-25
WO2004058233A1 (en) 2004-07-15
ECSP055855A (en) 2005-11-22
AU2003288226A1 (en) 2004-07-22
EP1581198A1 (en) 2005-10-05
RS20050484A (en) 2007-11-15
KR20050086930A (en) 2005-08-30
CN1728988B (en) 2010-04-28
BR0317443A (en) 2005-11-16
FR2848849A1 (en) 2004-06-25
CN1728988A (en) 2006-02-01
ITMI20032473A1 (en) 2004-06-21
FR2848849B1 (en) 2007-01-05
HRP20050570A2 (en) 2006-07-31
MXPA05006519A (en) 2005-08-26
AU2003288226B2 (en) 2010-01-07
JP2006516135A (en) 2006-06-22
UA83813C2 (en) 2008-08-26
DE10351663A1 (en) 2004-07-01
NO20053548L (en) 2005-09-02
EA010588B1 (en) 2008-10-30
EA200500902A1 (en) 2006-02-24

Similar Documents

Publication Publication Date Title
PL376231A1 (en) Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate
IL183623A0 (en) A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
HUP0400600A3 (en) Metered dose inhaler for salmeterol xinafoate
EP1581281A4 (en) Inhalation device for producing a drug aerosol
EG23792A (en) Inhalation device for transpulmonary administration
IL182634A0 (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
GB0313604D0 (en) Delivery device for powdered medicament
IL221103B (en) Inhaler for powdered substances particularly medical substances
SI1335728T1 (en) Medicament compositions based on tiotropium salts and on salmeterol salts
PL387118A1 (en) Inhalation capsules comprising tiotropium and the use thereof
EP1898922A4 (en) Improved drug or pharmaceutical compounds and a preparation thereof
GB0222295D0 (en) Breath actuated medicament dispensing devices
EP1685865A4 (en) A syringe for powder medicament premixing
GB0328630D0 (en) Metered dose inhalation preparations
GB0714907D0 (en) A resonating (alerting) metered dose inhaler
IL181819A (en) Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds
PL371204A1 (en) Aerosol formulation for inhalation comprising a tiotropium salt
PL376229A1 (en) Pulverulent formulation for inhalation containing tiotropium
TWI340649B (en) A pharmaceutical composition containing alkaline medicament
GB2406096B (en) A pharmaceutical metered dose aerosol inhaler device
ZA200406881B (en) Medicaments containing betamimetic drugs and a novel anticholineterase drug
GB0226274D0 (en) Metered dose inhalation preparations
AU6028101A (en) Medicament for combating respiratory depression
GB0311701D0 (en) Improved metered dose inhaler product
HK1084606A (en) Dry powder for inhalation comprising a formoterol salt and ciclesonide

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)